Recursion Pharmaceuticals Ownership | Who Owns Recursion Pharmaceuticals?
Recursion Pharmaceuticals Ownership Summary
Recursion Pharmaceuticals is owned by 92.31% institutional investors, 4.52% insiders, and 3.16% retail investors. Ark investment management is the largest institutional shareholder, holding 11.92% of RXRX shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 6.32% of its assets in Recursion Pharmaceuticals shares.
RXRX Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Recursion Pharmaceuticals | 92.31% | 4.52% | 3.16% |
Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
Industry | Biotech Stocks | 109.70% | 8.77% | -18.47% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Ark investment management | 28.14M | 11.92% | $211.07M |
Baillie gifford | 26.59M | 11.27% | $199.42M |
Vanguard group | 21.56M | 9.13% | $161.67M |
Blackrock | 17.31M | 7.33% | $129.83M |
Ra capital management | 15.38M | 6.52% | $115.38M |
Mubadala investment co pjsc | 12.99M | 5.50% | $97.39M |
Kinnevik ab (publ) | 11.91M | 4.21% | $80.48M |
Nikko asset management americas | 9.93M | 4.21% | $74.31M |
State street | 8.75M | 3.71% | $65.62M |
Mic capital management uk llp | 8.45M | 3.58% | $63.39M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Kinnevik ab (publ) | 11.91M | 100.00% | $80.48M |
Dcvc opportunity fund ii gp | 3.95M | 44.95% | $29.63M |
Data collective iv gp | 5.94M | 31.23% | $44.56M |
Nvidia | 7.71M | 14.70% | $57.80M |
Mic capital management uk llp | 8.45M | 13.78% | $63.39M |
Ark investment management | 28.14M | 1.87% | $211.07M |
Ra capital management | 15.38M | 1.53% | $115.38M |
Exor capital llp | 3.68M | 0.93% | $27.56M |
Nikko asset management americas | 9.93M | 0.86% | $74.31M |
Commons capital | 108.52K | 0.66% | $733.60K |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Ra capital management | 15.38M | 1.53% | 15.38M |
Vanguard group | 21.56M | 0.00% | 5.54M |
Blackrock | 17.31M | 0.00% | 4.99M |
Ark investment management | 28.14M | 1.87% | 3.56M |
Baillie gifford | 26.59M | 0.16% | 2.52M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Laurion capital management lp | - | - | -2.90M |
State street | 8.75M | 0.00% | -1.60M |
Platinum investment management | 395.67K | 0.12% | -1.40M |
Ghisallo capital management | - | - | -1.10M |
Fmr | 8.19M | 0.00% | -1.07M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Ra capital management | 15.38M | 1.53% | 15.38M | $115.38M |
Norges bank | 1.95M | 0.00% | 1.95M | $14.60M |
Woodline partners lp | 664.45K | 0.05% | 664.45K | $4.98M |
Neuberger berman group | 355.64K | 0.00% | 355.64K | $2.67M |
Scientech research | 140.29K | 0.22% | 140.29K | $1.05M |
Sold Out
Holder | Change |
---|---|
Financial gravity asset management | -4.00 |
Householder group estate & retirement specialist | -11.00 |
Gradient investments | -15.00 |
Corecap advisors | -26.00 |
Nelson, van denburg & campbell wealth management group | -28.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 275 | -1.43% | 260,863,978 | 3.59% | 92 | 0.81% | 154 | -13.97% | 49 | - |
Jun 30, 2024 | 277 | 8.20% | 251,804,695 | 20.07% | 106 | 1.35% | 177 | 12.74% | 49 | -5.77% |
Mar 31, 2024 | 256 | 25.49% | 209,712,724 | 1.55% | 88 | 1.13% | 157 | 38.94% | 52 | 15.56% |
Dec 31, 2023 | 204 | 2.00% | 206,519,352 | 35.69% | 88 | 1.76% | 113 | -14.39% | 45 | 25.00% |
Sep 30, 2023 | 200 | 25.79% | 152,197,134 | 19.37% | 71 | 1.77% | 132 | 57.14% | 36 | -14.29% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
ARK Disruptive Innovation Full Composite | 17.83M | 6.32% | 1.17M |
ARK Innovation ETF | 18.37M | 4.70% | -324.48K |
Scottish Mortgage Ord | 18.17M | 4.65% | - |
ARK Genomic Revolution | 12.71M | 4.50% | 3.20M |
Vanguard Total Stock Mkt Idx Inv | 11.59M | 2.97% | 3.92M |
ARK Genomic Revolution ETF | 11.57M | 2.96% | -475.38K |
Vanguard Small Cap Index | 9.23M | 2.36% | 2.98M |
SPDR® S&P Biotech ETF | 6.78M | 1.74% | -79.27K |
iShares Russell 2000 ETF | 6.71M | 1.72% | -25.75K |
Vanguard Small Cap Growth Index Inv | 5.25M | 1.34% | 1.80M |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jan 10, 2025 | Gibson Christopher | Chief Executive Officer | Sell | $141.00K |
Jan 08, 2025 | Gibson Christopher | Chief Executive Officer | Sell | $146.20K |
Dec 04, 2024 | Gibson Christopher | Chief Executive Officer | Sell | $143.20K |
Dec 05, 2024 | Gibson Christopher | Chief Executive Officer | Sell | $142.40K |
Nov 13, 2024 | Gibson Christopher | Chief Executive Officer | Sell | $154.80K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q4 | - | 15 |
2024 Q3 | - | 21 |
2024 Q2 | - | 22 |
2024 Q1 | - | 33 |
2023 Q4 | - | 27 |
RXRX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools